CYANOPHY Laboratoire SAS: EUR 30 million bond issuance to promote ecological innovation

Aix-en-Provence (pta008/15.07.2024/10:00 UTC+2)

CYANOPHY Laboratoire SAS (CH1365761050), a leader in active products extracted from microalgae, announces a EUR 30 million Convertible Bond issue to finance its strategic development. This initiative aims to strengthen the company's capabilities by acquiring liposomal technology and setting up state-of-the-art microalgae facilities in France and Portugal.

Investment opportunity for qualified investors

The Convertible Bond will be listed on the Vienna Stock Exchange (Wiener Börse). The Bond converts into shares that offers an attractive annual coupon of 5% (five percent) over three years, with incentive conversion options throughout its term. This bond is a unique opportunity for qualified investors to support the ecological transition and the shift from synthetic to natural health treatments.

Strategic expansion and technological progress

CYANOPHY Laboratoire specialises in microalgae cultivation, eco-extraction of high-purity active products and stabilisation using the liposome technique. The company's innovative research has developed promising biomolecules for pharmacology and medicine, focusing on cellular health.

To advance its research and development, CYANOPHY Laboratoire plans to:

- Acquire liposomal technology from a Belgian company
- Build a spirulina cultivation unit in Avignon (Mas Faracha - France)
- Set up a spirulina cultivation, phycocyanin extraction and liposomal processing complex in Coruche (Craolus - Portugal)
- Building a new head office in Aix-en-Provence, including facilities for the eco-extraction of phycocyanin and liposomal processing

These new facilities will be "green electricity positive", producing their own energy "in-house", utilizing photovoltaic power stations.

General terms and conditions of the convertible bond

- Issuer: CYANOPHY Laboratoire SAS
- Listing: Vienna Stock Exchange, MTF Segment
- ISIN Code: CH1365761050
- Amount of bond issue (intermediate securities, "Wertrechte"): EUR 30 million
- Term of issue: 3 years
- Minimum investment: EUR 100,000
- Interest rate/coupon: 5% gross per annum
- Redemption: Principal at maturity
- Conversion, available at any time during the term of the bond:

• Year 1: EUR 100,000 converted into 833 shares (20% discount, conversion price per share: EUR 120.00)
• Year 2: EUR 100,000 converted into 741 shares (10% discount, conversion price per share: EUR 135.00)
• Year 3: EUR 100,000 converted into 702 shares (5% discount, conversion price per share: EUR 142.50)
• End of period: EUR 100,000 converted into 667 shares (0% discount, conversion price per share: EUR 150.00)

- Interest payment: annually
- Nominal value CL share: EUR 20

Contact
For investors, media and analyst enquiries, please contact:
Harald Gruber, Investor Relations Manager (IR), CYANOPHY Laboratoire
Telephone: +41 79 897 71 84
E-mail: gruber@gruberconsult.ch

About CYANOPHY Laboratoire SAS
CYANOPHY Laboratoire SAS is at the forefront of innovation in cellular health, using high-purity extracts of phycocyanin and astaxanthin. These pigments are renowned for their antioxidant and anti-inflammatory properties, and are beneficial for the metabolism and the microbiota. The liposomal form of phycocyanin, with its unique stability and high concentration, testifies CYANOPHY's commitment to invent and market advanced and natural health solutions.

For further information please visit https://cyanophy.com

(end)

Emitter:	CYANOPHY Laboratoire SAS Les Carrés de L'enfant - Bâtiment E - Avenue du 12 Juillet 1998 13080 Aix-en-Provence France
Contact Person:	Harald Gruber, Investor Relations Manager (IR)
Phone:	+41 79 897 71 84
E-Mail:	gruber@gruberconsult.ch
Website:	www.cyanophy.com
ISIN(s):	CH1365761050 (Bond)
Stock Exchange(s):	Vienna Stock Exchange (Vienna MTF)